GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Sale Of Investment

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Sale Of Investment : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Sale Of Investment?

Aequus Pharmaceuticals's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Aequus Pharmaceuticals gained $0.00 Mil from selling investments. Aequus Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2022 ), Aequus Pharmaceuticals gained the same money from selling investments in Sep. 2023 ($0.00 Mil).


Aequus Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for Aequus Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Sale Of Investment Chart

Aequus Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aequus Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aequus Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Headlines

From GuruFocus

Aequus Reports Third Quarter 2022 Financial Highlights

By GlobeNewswire GlobeNewswire 11-30-2022

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-03-2022

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 06-26-2022

Aequus Resumes Trading on TSX Venture Exchange

By PurpleRose PurpleRose 07-13-2022

Aequus Reports Third Quarter 2022 Financial Highlights

By Value_Insider Value_Insider 11-30-2022

Aequus Announces Zimed PF Website Launch

By Marketwired 08-22-2023